Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CRDF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 26.53M
March 31, 2026 34.71M
December 31, 2025 45.39M
September 30, 2025 48.79M
June 30, 2025 58.61M
March 31, 2025 70.88M
December 31, 2024 82.95M
September 30, 2024 49.39M
June 30, 2024 52.39M
March 31, 2024 60.89M
December 31, 2023 69.74M
September 30, 2023 77.83M
June 30, 2023 86.58M
March 31, 2023 96.50M
December 31, 2022 106.34M
September 30, 2022 113.21M
June 30, 2022 120.47M
March 31, 2022 130.10M
December 31, 2021 140.56M
September 30, 2021 133.54M
June 30, 2021 138.92M
March 31, 2021 124.82M
December 31, 2020 130.33M
September 30, 2020 33.52M
June 30, 2020 24.38M
Date Value
March 31, 2020 6.143M
December 31, 2019 8.283M
September 30, 2019 6.656M
June 30, 2019 8.848M
March 31, 2019 9.686M
December 31, 2018 10.08M
September 30, 2018 13.98M
June 30, 2018 17.48M
March 31, 2018 4.679M
December 31, 2017 6.506M
September 30, 2017 3.945M
June 30, 2017 3.511M
March 31, 2017 10.68M
December 31, 2016 19.77M
September 30, 2016 26.77M
June 30, 2016 32.57M
March 31, 2016 41.16M
December 31, 2015 48.70M
September 30, 2015 54.86M
June 30, 2015 18.12M
March 31, 2015 23.56M
December 31, 2014 8.350M
September 30, 2014 12.35M
June 30, 2014 17.33M
March 31, 2014 17.75M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Ocugen, Inc. -16.56M
CytomX Therapeutics, Inc. 302.07M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M

Shareholders Equity (Quarterly) Related Metrics